Mural Oncology Plc is a clinical-stage company developing cytokine-based immunotherapies for cancer using its protein engineering platform. Its portfolio includes Nemvaleukin alfa and a tumor-targeted split IL-12 program.
Vicki L Goodman sold 13,186 shares of MURA on 24 February at $3.89 per share, worth a total of $51K. They now own 54,763 MURA shares, or a 19% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
